Jorg Klingelhofer

Copenhagen, Denmark

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.

A first-in-human study of CAL101, a monoclonal antibody targeting S100A4.

Journal: British journal of clinical pharmacology

Published: April 01, 2026

Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.

Development of CAL101-a humanized monoclonal antibody targeting S100A4 to inhibit proinflammatory and profibrotic signaling.

Journal: The Journal of pharmacology and experimental therapeutics

Published: June 24, 2025

Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.

Effect of Anti-S100A4 Monoclonal Antibody Treatment on Experimental Skin Fibrosis and Systemic Sclerosis-Specific Transcriptional Signatures in Human Skin.

Journal: Arthritis & rheumatology (Hoboken, N.J.)

Published: February 22, 2023

S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

S100A4-neutralizing monoclonal antibody 6B12 counteracts the established experimental skin fibrosis induced by bleomycin.

Journal: Rheumatology (Oxford, England)

Published: February 17, 2023

Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.

Clinical and pathogenic significance of S100A4 overexpression in systemic sclerosis.

Journal: Annals of the rheumatic diseases

Published: January 07, 2023

Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor.

Anti-S100A4 Antibody Therapy Is Efficient in Treating Aggressive Prostate Cancer and Reversing Immunosuppression: Serum and Biopsy S100A4 as a Clinical Predictor.

Journal: Molecular cancer therapeutics

Published: May 15, 2020

Neurotrophic Effects of Vascular Endothelial Growth Factor B and Novel Mimetic Peptides on Neurons from the Central Nervous System.

Neurotrophic Effects of Vascular Endothelial Growth Factor B and Novel Mimetic Peptides on Neurons from the Central Nervous System.

Journal: ACS chemical neuroscience

Published: April 14, 2020

Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells.

Neutralization of S100A4 induces stabilization of atherosclerotic plaques: role of smooth muscle cells.

Journal: Cardiovascular research

Published: March 31, 2020

The Multifaceted S100A4 Protein in Cancer and Inflammation.

The Multifaceted S100A4 Protein in Cancer and Inflammation.

Journal: Methods in molecular biology (Clifton, N.J.)

Published: February 03, 2019

The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival.

The S100A4 Protein Signals through the ErbB4 Receptor to Promote Neuronal Survival.

Journal: Theranostics

Published: August 08, 2017

S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.

S100A4-neutralizing antibody suppresses spontaneous tumor progression, pre-metastatic niche formation and alters T-cell polarization balance.

Journal: BMC cancer

Published: October 10, 2014

A generally applicable translational strategy identifies S100A4 as a candidate gene in allergy.

A generally applicable translational strategy identifies S100A4 as a candidate gene in allergy.

Journal: Science translational medicine

Published: January 10, 2014

Showing 1-12 of 16

Last Updated: 09/26/2026